HighMark Wealth Management’s Bicycle Therapeutics BCYC Stock Holding History

HighMark Wealth Management’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.84K	Hold	435	–	–	﹤0.01%	468
2026 Q1	$2.02K	Hold	435	–	–	﹤0.01%	458
2025 Q4	$3.08K	Hold	435	–	–	﹤0.01%	452
2025 Q3	$3.37K	Hold	435	–	–	﹤0.01%	443
2025 Q2	$3.02K	Hold	435	–	–	﹤0.01%	452
2025 Q1	$3.69K	Sell	435 -4,000	-90%	-$47.1K	﹤0.01%	399
2024 Q4	$62.1K	Hold	4,435	–	–	0.04%	109
2024 Q3	$100K	Hold	4,435	–	–	0.05%	101
2024 Q2	$89.8K	Hold	4,435	–	–	0.05%	106
2024 Q1	$110K	Hold	4,435	–	–	0.07%	93
2023 Q4	$80.2K	Hold	4,435	–	–	0.06%	105
2023 Q3	$89.1K	Buy	4,435 +200	+5%	+$4.57K	0.07%	85
2023 Q2	$108K	Hold	4,235	–	–	0.08%	78
2023 Q1	$90.1K	Hold	4,235	–	–	0.07%	102
2022 Q4	$125K	Hold	4,235	–	–	0.09%	67
2022 Q3	$99K	Hold	4,235	–	–	0.08%	70
2022 Q2	$71K	Hold	4,235	–	–	0.06%	83
2022 Q1	$186K	Sell	4,235 -90	-2%	-$4.2K	0.12%	57
2021 Q4	$263K	Buy	4,325 +3,699	+591%	+$204K	0.17%	46
2021 Q3	$26K	Buy	+626	New	+$21.9K	0.02%	161

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GSK plc London $602M AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

HighMark Wealth Management's BCYC Position: Q2 2026 in Review

HighMark Wealth Management held its Bicycle Therapeutics (BCYC) position steady in Q2 2026 at 435 shares worth $1.84K. The position accounts for ﹤0.01% of the portfolio, ranked #468.

HighMark Wealth Management first reported a position in BCYC in Q3 2021 and has held it in 20 quarters since. The position peaked at $263K in Q4 2021. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

HighMark Wealth Management held 435 shares of Bicycle Therapeutics worth $1.84K as of Q2 2026.
HighMark Wealth Management left its Bicycle Therapeutics share count unchanged in Q2 2026.
Bicycle Therapeutics made up ﹤0.01% of HighMark Wealth Management's portfolio in Q2 2026, its #468 holding.
HighMark Wealth Management first reported a position in Bicycle Therapeutics in Q3 2021 and has held it in 20 quarters since.
HighMark Wealth Management's Bicycle Therapeutics position peaked at $263K in Q4 2021.
104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.